OGB 23502
Alternative Names: OGB-23502Latest Information Update: 09 Dec 2021
Price :
$50 *
At a glance
- Originator Onegene Biotechnology
- Class Antibodies; Antineoplastics; Immunoconjugates; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death 1 receptor antagonists; Vascular endothelial growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 07 Dec 2021 Early research in Cancer in South Korea (Parenteral) before December 2021 (Onegene Biotechnology pipeline, December 2021)